| Target Molecule | Enfuvirtide |
| Synonyms | Fuzeon, T-20, DP-178, ENF, Pentafuside, gp41(127-162) |
| CAS Number | 159519-65-0 |
| Sequence (3-Letter) | Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH₂ |
| Sequence (1-Letter) | Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH₂ |
| Molecular Formula | C₂₀₄H₃₀₁N₅₁O₆₄ |
| Molecular Weight | 4492 (≈ 4491.88) |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98% via HPLC) |
| Appearance | White to off-white amorphous powder |
| Counter Ion | Acetate (standard pharmaceutical salt), TFA, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and Hybrid Fragment Condensation for Long Chains |
| Modification Options | N-terminal acetylation, C-terminal amidation, stable isotope labeling (13C, 15N), deletion sequence impurity standards |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and sequence confirmation provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Enfuvirtide (CAS 159519-65-0), also known as Fuzeon or T-20, is a 36-amino-acid linear peptide featuring N-terminal acetylation and C-terminal amidation (Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH₂). We target this sequence to supply high-purity reference materials, analytical standards, and raw materials for HIV fusion inhibitor and antiviral research.
Assembling a 36-residue chain carries extreme risks of sequence truncation, aggregation, and incomplete coupling cycles. Our peptide synthesis platform utilizes optimized Solid-Phase Peptide Synthesis (SPPS) protocols on low-loading resins, high-efficiency coupling reagents, and hybrid fragment-condensation strategies to ensure high-fidelity assembly.
Yes. We provide specialized peptide modification services for long-chain antivirals. Options include site-specific stable isotope labeling (13C, 15N) for quantitative mass spectrometry (LC-MS/MS), fluorescent or biotin tagging, and the synthesis of specific deletion sequences as stability-indicating impurity reference standards.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (ensuring acetate salt conversion) to guarantee strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, impurity profiling, analytical method validation, and regulatory documentation to accelerate complex preclinical and commercial pipelines.
Enfuvirtide (CAS 159519-65-0), historically referenced under the code T-20 and commercialized as Fuzeon, is a synthetic 36-amino-acid peptide acting as an HIV-1 fusion inhibitor. Defined by the acetylated and amidated sequence Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH₂, it represents a landmark achievement in large-scale long-chain peptide manufacturing. Synpeptide delivers comprehensive custom synthesis solutions for this target molecule, showcasing our technical capabilities in long-chain SPPS, fragment condensation, and CDMO manufacturing.
Constructing a 36-amino acid sequence requires exceptional chemical precision and process engineering to prevent cumulative deletion errors and on-resin aggregation. Our custom peptide synthesis platform resolves these hurdles using advanced manufacturing protocols, combining continuous Solid-Phase Peptide Synthesis (SPPS) with hybrid solution-phase fragment condensation. By deploying high-efficiency coupling reagents, temperature control, and complete N-terminal acetyl capping, we suppress truncated byproducts, delivering raw materials with rigorous purity specifications (typically ≥95% or ≥98% via HPLC).
Because long-chain peptides frequently contain deletion sequences and truncated fragments, robust analytical validation is essential. Through our peptide modification services, we synthesize defined deletion analogues and truncated variants to serve as critical impurity reference standards for stability-indicating assays. We also offer stable isotope labeling (13C, 15N) for pharmacokinetic bioanalysis and fluorescent conjugates for viral entry studies.
Transitioning a 36-residue peptide from laboratory research to commercial scale demands robust chemical engineering during downstream chromatographic isolation. We execute large-scale peptide synthesis for Enfuvirtide by optimizing fluid dynamics and high-capacity preparative HPLC purification. Our facilities accommodate requirements from milligram research batches to kilogram commercial lots, ensuring uniform counter-ion exchange (consistently achieving the pharmaceutical acetate salt form) and reproducible lyophilization profiles across all production volumes.
We deliver comprehensive technical support as a fully established peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream clinical-stage programs.
